Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corp, a Delaware corporation, on January 2, 2024, reporting an event that occurred on December 27, 2023. The company is incorporated in Delaware and maintains its principal executive offices in Burlington, MA. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols BBLG and BBLGW, respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director.
- The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. Management expressed appreciation for Mr. Lucera's years of service.
Key Facts for Investor Verification
- Verify the identity and qualifications of the new director appointed to replace Erick Lucera.
- Confirm the effective date of the new director's appointment to ensure board quorum and governance continuity.
- Review subsequent filings for any financial updates or strategic shifts following this governance change.